JP2025507852A5 - - Google Patents

Info

Publication number
JP2025507852A5
JP2025507852A5 JP2024551975A JP2024551975A JP2025507852A5 JP 2025507852 A5 JP2025507852 A5 JP 2025507852A5 JP 2024551975 A JP2024551975 A JP 2024551975A JP 2024551975 A JP2024551975 A JP 2024551975A JP 2025507852 A5 JP2025507852 A5 JP 2025507852A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
compound according
aforementioned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024551975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507852A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/014275 external-priority patent/WO2023167925A1/en
Publication of JP2025507852A publication Critical patent/JP2025507852A/ja
Publication of JP2025507852A5 publication Critical patent/JP2025507852A5/ja
Pending legal-status Critical Current

Links

JP2024551975A 2022-03-01 2023-03-01 中環状または大環状ベンジル置換複素環誘導体および関連の使用 Pending JP2025507852A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263315438P 2022-03-01 2022-03-01
US63/315,438 2022-03-01
US202363439477P 2023-01-17 2023-01-17
US63/439,477 2023-01-17
PCT/US2023/014275 WO2023167925A1 (en) 2022-03-01 2023-03-01 Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses

Publications (2)

Publication Number Publication Date
JP2025507852A JP2025507852A (ja) 2025-03-21
JP2025507852A5 true JP2025507852A5 (cg-RX-API-DMAC7.html) 2026-03-10

Family

ID=85772026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024551975A Pending JP2025507852A (ja) 2022-03-01 2023-03-01 中環状または大環状ベンジル置換複素環誘導体および関連の使用

Country Status (12)

Country Link
US (2) US20250236629A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486748A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025507852A (cg-RX-API-DMAC7.html)
KR (1) KR20240157067A (cg-RX-API-DMAC7.html)
CN (1) CN119110802A (cg-RX-API-DMAC7.html)
AU (1) AU2023228830A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245204A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002576A1 (cg-RX-API-DMAC7.html)
IL (1) IL315237A (cg-RX-API-DMAC7.html)
MX (1) MX2024010608A (cg-RX-API-DMAC7.html)
TW (1) TW202400606A (cg-RX-API-DMAC7.html)
WO (1) WO2023167925A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
EP4680611A1 (en) 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
JP2026518313A (ja) 2023-06-01 2026-06-04 ハー・ルンドベック・アクチエゼルスカベット スピロ大環状オレキシン2受容体アゴニスト
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
US20260144795A1 (en) 2024-11-27 2026-05-28 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US10428023B2 (en) 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
PE20211700A1 (es) 2019-01-31 2021-09-01 Takeda Pharmaceuticals Co Compuesto heterociclico y su uso
KR20260083444A (ko) * 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
CN116635393A (zh) * 2020-09-03 2023-08-22 欧瑞夏治疗有限公司 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途

Similar Documents

Publication Publication Date Title
JP2023540350A5 (cg-RX-API-DMAC7.html)
JP2023540344A5 (cg-RX-API-DMAC7.html)
JP2023527575A5 (cg-RX-API-DMAC7.html)
JP4628974B2 (ja) イバブラジン塩酸塩のγ−結晶形態、その製造方法およびそれを含む医薬組成物
JP2022545633A5 (cg-RX-API-DMAC7.html)
CN116438170A (zh) 含氮桥杂环化合物、其制备方法及其在医药上的应用
JP2023502441A5 (cg-RX-API-DMAC7.html)
JP2021513967A5 (cg-RX-API-DMAC7.html)
JP2014528485A5 (cg-RX-API-DMAC7.html)
JPH06510030A (ja) 新規な3,5−ジ−tert−ブチル−4− ヒドロキシフェニル誘導体、それらの製造方法および薬剤
JP2006504710A5 (cg-RX-API-DMAC7.html)
JP2022530989A5 (cg-RX-API-DMAC7.html)
NO338370B1 (no) ß-krystallinsk form av ivabradin-hydroklorid, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den
JPH0544946B2 (cg-RX-API-DMAC7.html)
JP2007112796A (ja) 塩酸イバブラジンのδ結晶形態、その製造法、およびそれを含有する医薬組成物
RS50599B (sr) KRISTALNI OBLIK BETA-d IVABRADIN HLORHIDRATA, POSTUPAK NJEGOVE IZRADE I FARMACEUTSKE SMEŠE KOJE GA SADRŽE
JP2007519742A5 (cg-RX-API-DMAC7.html)
JPH02290841A (ja) 新規化合物、その製法及びそれを含む医薬組成物
JP2022174180A (ja) 化合物、組成物および方法
JPH07508973A (ja) 血中酸素親和性の抑制のためのヘモグロビンのアロステリック修飾剤の使用
AU2021328979B2 (en) Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof
JP2022526827A (ja) (e)-3-[2-(2-チエニル)ビニル]-1h-ピラゾールの固体形態
US8912214B2 (en) Use of Chk2 kinase inhibitors for cancer treatment
JPH05194491A (ja) イミダゾリルメチル−ピリジン
JP7235671B2 (ja) H3リガンドの四水和物、その製造方法及びそれを含む医薬組成物